» Articles » PMID: 34337521

Photodynamic Diagnosis-guided Dual Laser Ablation for Upper Urinary Tract Carcinoma: Preoperative Preparation, Surgical Technique, and Clinical Outcomes

Overview
Date 2021 Aug 2
PMID 34337521
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although ureteroscopic surgery (URS) is beneficial for low-risk upper urinary tract carcinoma (UTUC), there is no standardized URS technique or navigation system for challenging cases.

Objective: To present a URS technique for UTUC using thulium (Tm):YAG and holmium (Ho):YAG lasers under photodynamic diagnosis (PDD) guidance, named PDD-guided dual laser ablation (PDD-DLA) and compare its efficacy with that of conventional Ho:YAG laser ablation (HLA; historical control).

Design Setting And Participants: The study included ten consecutive UTUC patients who underwent PDD-DLA between 2017 and 2019. The control group comprised 16 consecutive patients who underwent HLA between 2006 and 2016.

Surgical Procedure: After oral administration of 5-aminolevulinic acid (20 mg/kg), UTUC tumors were endoscopically resected via PDD-DLA.

Measurements: Clinical data were prospectively collected for our institutional UTUC data set. Disease progression, UTUC recurrence, and clinical outcomes were assessed.

Results And Limitations: PDD-DLA was successfully performed in all patients. The median tumor size was 23.5 mm (interquartile range [IQR] 12.8-30.0) and there were four cases (40.0%) of high-grade tumor. The median operative time was 120 min (IQR 98.5-142.5). No Clavien-Dindo grade ≥3 complications were observed. There were no differences in most clinical characteristics between the PDD-DLA and HLA groups. The 2-yr progression-free survival rate was 100% in the PDD-DLA group and 58.7% in the HLA group ( = 0.0197), and the 2-yr recurrence-free survival rate was 57.1% and 41.3%, respectively ( = 0.072). The PDD-DLA group had a lower incidence rate of salvage RNU compared with the HLA group (0.0% vs 50%;  = 0.009). The small sample size might affect the reproducibility of these results.

Conclusions: PDD-DLA seems to be an effective and feasible endoscopic technique for UTUC treatment with favorable oncological outcomes.

Patient Summary: We investigated a new laser technique for treating cancer of the upper urinary tract called photodynamic diagnosis-guided dual laser ablation. Our strategy was effective in removing tumors and stopping bleeding. Further studies in larger groups of patients are needed to confirm whether this technique improves cancer outcomes.

Citing Articles

Reply to: "Photodynamic Diagnosis-Guided Ureteroscopic Laser Ablation of Upper Tract Urothelial Carcinoma: Some Concerns and Future Direction".

Yoshida T, Rogers C, Raza J, Matsuda T, Kinoshita H Ann Surg Oncol. 2025; .

PMID: 40089618 DOI: 10.1245/s10434-025-17172-5.


Photodynamic Diagnosis-Guided Ureteroscopic Laser Ablation of Upper Tract Urothelial Carcinoma: Some Concerns and Future Direction.

Katayama S, Iwata T, Nishimura S, Bekku K, Araki M Ann Surg Oncol. 2025; .

PMID: 39982549 DOI: 10.1245/s10434-025-17017-1.


Photodynamic Diagnosis-Guided Ureteroscopic Laser Ablation of Upper Urinary Tract Urothelial Carcinoma: Phase 2, Open-Label, Single-Arm Trial.

Yoshida T, Motoki Y, Rogers C, Raza J, Nakamoto T, Matsuda T Ann Surg Oncol. 2024; 32(1):35-38.

PMID: 39402321 PMC: 11659339. DOI: 10.1245/s10434-024-16351-0.


Navigating the Aftermath: A Comprehensive Scoping Review on Follow-up Strategies After Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma.

Schuil H, Figaroa O, Hendriks N, Schout B, Beerlage H, van Jamaludin F Eur Urol Open Sci. 2024; 66:82-92.

PMID: 39050911 PMC: 11268123. DOI: 10.1016/j.euros.2024.06.005.


The role of endoscopic management and adjuvant topical therapy for upper tract urothelial cancer.

Chien A, Chua K, Doppalapudi S, Ghodoussipour S Front Urol. 2024; 2.

PMID: 38855025 PMC: 11160966. DOI: 10.3389/fruro.2022.916259.


References
1.
Villa L, Haddad M, Capitanio U, Somani B, Cloutier J, Doizi S . Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. J Urol. 2017; 199(1):66-73. DOI: 10.1016/j.juro.2017.07.088. View

2.
Proietti S, Rodriguez-Socarras M, Eisner B, Luciano R, Basulto Martinez M, Yeow Y . Thulium:YAG Holmium:YAG Laser Effect on Upper Urinary Tract Soft Tissue: Evidence from an Experimental Study. J Endourol. 2020; 35(4):544-551. DOI: 10.1089/end.2020.0222. View

3.
Cutress M, Stewart G, Wells-Cole S, Phipps S, Thomas B, Tolley D . Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012; 110(11):1608-17. DOI: 10.1111/j.1464-410X.2012.11169.x. View

4.
Defidio L, DE Dominicis M, Di Gianfrancesco L, Fuchs G, Patel A . First collaborative experience with thulium laser ablation of localized upper urinary tract urothelial tumors using retrograde intra-renal surgery. Arch Ital Urol Androl. 2011; 83(3):147-53. View

5.
Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu J . Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2015; 34(9):1201-6. DOI: 10.1007/s00345-015-1753-7. View